JCEM:度拉糖肽对老年患者疗效和安全性分析

2021-02-06 MedSci原创 MedSci原创

度拉糖肽对≥65岁和<65岁的患者具类似的疗效和安全性。

在REWIND试验中,度拉糖肽可减少主要不良血管事件(MACE)。尚未研究比较其在老年患者和年轻患者中的疗效和安全性。近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,研究人员旨在按年龄亚组(≥65岁和<65岁)评估度拉糖肽与安慰剂的疗效和安全性。

该研究为针对REWIND试验的亚组分析,参与者为年龄50岁以上的2型糖尿病患者,他们伴有明确的CV疾病或多种CV危险因素,并且接受了血糖控制。患者随机(以1:1比例)将1.5 mg度拉糖肽或安慰剂加入到标准治疗方案中,该研究的主要观察指标为MACE(非致命性心肌梗死、非致命性卒中或因CV或未知原因死亡的复合事件)。

5256名患者年龄≥65岁(平均=71.0),4645名患者年龄<65岁(平均=60.7)。随机治疗组间基线特征相似。在老年患者和年轻患者中,度拉糖肽治疗降低MACE发生率的效果相似(11% vs. 13%)。在每个年龄亚组的随机治疗组之间,永久性停用研究药物、全因死亡、心力衰竭住院、严重低血糖、严重肾脏或泌尿事件以及严重胃肠道事件发生率相似。在每个年龄亚组中,度拉糖肽组的严重心脏传导障碍的发生率数据上均高于安慰剂组,但差异无统计学意义。

由此可见,度拉糖肽对≥65岁和<65岁的患者具类似的疗效和安全性

原始出处:

Matthew C Riddle.et al.Efficacy and Safety of Dulaglutide in Older Patients: A Post-hoc Analysis of the REWIND trial.JCEM.2021.https://doi.org/10.1210/clinem/dgab065

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1778020, encodeId=01c11e780205a, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Nov 05 02:14:05 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063402, encodeId=e53920634021f, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Sep 27 21:14:05 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720989, encodeId=25171e20989a7, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Sep 13 15:14:05 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322664, encodeId=330f1322664fd, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49391, encryptionId=d5764939166, topicName=度拉糖肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Feb 08 04:14:05 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032789, encodeId=79441032e8911, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Feb 06 16:14:05 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
    2021-11-05 smallant2015
  2. [GetPortalCommentsPageByObjectIdResponse(id=1778020, encodeId=01c11e780205a, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Nov 05 02:14:05 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063402, encodeId=e53920634021f, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Sep 27 21:14:05 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720989, encodeId=25171e20989a7, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Sep 13 15:14:05 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322664, encodeId=330f1322664fd, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49391, encryptionId=d5764939166, topicName=度拉糖肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Feb 08 04:14:05 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032789, encodeId=79441032e8911, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Feb 06 16:14:05 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
    2021-09-27 achengzhao
  3. [GetPortalCommentsPageByObjectIdResponse(id=1778020, encodeId=01c11e780205a, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Nov 05 02:14:05 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063402, encodeId=e53920634021f, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Sep 27 21:14:05 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720989, encodeId=25171e20989a7, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Sep 13 15:14:05 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322664, encodeId=330f1322664fd, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49391, encryptionId=d5764939166, topicName=度拉糖肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Feb 08 04:14:05 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032789, encodeId=79441032e8911, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Feb 06 16:14:05 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1778020, encodeId=01c11e780205a, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Nov 05 02:14:05 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063402, encodeId=e53920634021f, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Sep 27 21:14:05 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720989, encodeId=25171e20989a7, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Sep 13 15:14:05 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322664, encodeId=330f1322664fd, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49391, encryptionId=d5764939166, topicName=度拉糖肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Feb 08 04:14:05 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032789, encodeId=79441032e8911, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Feb 06 16:14:05 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1778020, encodeId=01c11e780205a, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Nov 05 02:14:05 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063402, encodeId=e53920634021f, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Sep 27 21:14:05 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720989, encodeId=25171e20989a7, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Sep 13 15:14:05 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322664, encodeId=330f1322664fd, content=<a href='/topic/show?id=d5764939166' target=_blank style='color:#2F92EE;'>#度拉糖肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49391, encryptionId=d5764939166, topicName=度拉糖肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Mon Feb 08 04:14:05 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032789, encodeId=79441032e8911, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Feb 06 16:14:05 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
    2021-02-06 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

Ann Rheum Dis:乌帕替尼治疗类风湿性关节炎的安全性

与阿达木单抗相比,乌帕替尼治疗的患者带状疱疹和CPK升高的风险增加。乌帕替尼、甲氨蝶呤或阿达木单抗治疗的患者恶性肿瘤、MACE和VTE的发生率相似。

JACC:美国超500万患者研究显示,近10%的PCI用于治疗支架内再狭窄

经皮冠状动脉介入治疗(PCI)是目前冠心病治疗的主要手段之一,极大改善了冠心病患者的预后,但介入治疗后再狭窄一直是其无法摆脱的梦魇。

JNNP:Erenumab对发作性偏头痛患者功能结果的影响

Erenumab是一种全人类单克隆抗体,可抑制典型降钙素基因相关肽(CGRP)受体。临床研究已证明Erenumab对发作性偏头痛(EM)和慢性偏头痛(CM)患者的疗效和安全性,包括先前预防性偏头痛治疗

TCT 2020|VOYAGER PAD研究:药物涂层装置在外周动脉血运重建中长期安全性得到认可

认可 对于有症状的外周动脉疾病(PAD)患者,腔内血运重建可有效改善症状及保肢率,但存在术后再狭窄的困扰。紫杉醇药物涂层装置(DCB)的设计初衷就是为了解决再狭窄问题以及改善通畅率。

Int Arch Allergy Immunol:过敏性鼻炎儿童特异性舌下免疫治疗安全性的风险因素研究

良好的依从性往往归因于舌下免疫疗法(SLIT)的良好疗效和安全性。然而,很少有关于儿童SLIT治疗安全性的研究。

Prostate Cancer:纳米体多烯紫杉醇脂悬液在转移去势抵抗性前列腺癌中的多中心、回顾性疗效和安全性研究

最近,有研究人员评估了纳米多烯紫杉醇脂悬液(NDLS,DoceAqualip)在转移去势抵抗性前列腺癌(mCRPC)患者中的疗效和安全性。